For almost two years, patients with Fabry's disease have been dealing with severe shortages of the medicine they need — Genzyme's Fabrazyme — as Genzyme deals with manufacturing problems and contamination. A year ago, the patients asked NIH to step in and demand that Genzyme allow other drug companies to make Fabrazyme, a provision known as "march-in" rights that NIH can exercise under certain circumstances according to the Bayh-Dole Act.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.